Approved adjuvant therapy options for melanoma are currently limited, with the standard of care being interferon-alpha. However, new options are on the horizon, including ipilimumab (Yervoy), which is being studied for melanoma in the adjuvant setting as part of several trials.
Conferences
MMP 2014 Community Questions Report regarding access to clinical trials for rural vs metropolitan patients.
Thank you to everyone that participated in our survey. You were obviously passionate about the ‘rural vs metro access to clinical trials’ topic as 216 of you participated. Your contribution…
Read More Melbourne Melanoma Project (MMP) 2014 Scientific Exchange Meeting – December 11th 2014
The 2014 MMP Scientific Exchange was well supported by all members of the melanoma community. Patients, carers, doctors, health professionals, researchers, pharmaceutical company representatives and Department of Health staff attended the event.
SMR 2014: More Good News on Pembrolizumab for Melanoma Patients Without Other Options
Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.